Omnicell (NASDAQ:OMCL) EVP Corey Manley Sells 6,106 Shares of Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 6,106 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the transaction, the executive vice president owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Omnicell Stock Up 0.9%

OMCL opened at $51.19 on Tuesday. The stock’s 50 day moving average price is $41.42 and its 200 day moving average price is $34.48. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.21. The stock has a market cap of $2.30 billion, a P/E ratio of 119.05, a P/E/G ratio of 5.40 and a beta of 0.77. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $51.30.

Institutional Trading of Omnicell

A number of large investors have recently added to or reduced their stakes in OMCL. Raymond James Financial Inc. bought a new position in shares of Omnicell in the second quarter valued at $26,000. First Horizon Corp acquired a new position in shares of Omnicell in the 3rd quarter worth $31,000. Farther Finance Advisors LLC raised its position in shares of Omnicell by 784.8% during the third quarter. Farther Finance Advisors LLC now owns 1,168 shares of the company’s stock worth $36,000 after purchasing an additional 1,036 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Omnicell by 37.1% during the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock valued at $50,000 after purchasing an additional 458 shares during the last quarter. Finally, LSV Asset Management acquired a new position in shares of Omnicell in the 3rd quarter valued at $97,000. 97.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

OMCL has been the topic of several research analyst reports. Zacks Research cut shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 9th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Omnicell in a report on Wednesday, October 8th. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective on the stock in a research note on Wednesday, January 7th. Wells Fargo & Company upped their target price on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Finally, Benchmark lifted their price target on Omnicell from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Omnicell has a consensus rating of “Hold” and a consensus target price of $47.83.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.